Anivance AI Corporation
Anivance AI provides human-relevant organ-on-chip systems to make preclinical testing faster and more predictive. It combines organ-on-chip hardware, automated high-throughput experimentation, and Multi-Agent AI for experiment design, real-time analysis, and self-optimizing workflows. The company operates as a B2B SaaS serving pharmaceutical companies, biotech firms, and clinical institutions and supports validated lung, liver, heart, kidney, tumor, and rare-disease models. Anivance leverages Taiwan’s semiconductor and precision-manufacturing ecosystem and accumulated clinical datasets to scale and validate its AI-driven preclinical solutions globally.
Anivance AI Corporation
Anivance AI provides human-relevant organ-on-chip systems to make preclinical testing faster and more predictive. It combines organ-on-chip hardware, automated high-throughput experimentation, and Multi-Agent AI for experiment design, real-time analysis, and self-optimizing workflows. The company operates as a B2B SaaS serving pharmaceutical companies, biotech firms, and clinical institutions and supports validated lung, liver, heart, kidney, tumor, and rare-disease models. Anivance leverages Taiwan’s semiconductor and precision-manufacturing ecosystem and accumulated clinical datasets to scale and validate its AI-driven preclinical solutions globally.